HemaCell
Latest round
- Series B
Last raised
- Jun 2026
Total raised
- $20M
Investors
- 14
About HemaCell
, trading as HemaCell, is a stem cell biomedical company that focuses on the research and development of blood platelet medical products. The company's founder Fangfang Zhu, graduated from Peking University, and she was Vice president of WI Harper Group. The founder team members graduated from Stanford University, Harvard University, Peking University, etc. As of 2022, the company has 121 patents and 342 employees. The company engaged in cell therapy and drug development based on stem cells to bring blood regeneration. Its products can be used to treat blood system-related diseases, cancer radiotherapy and chemotherapy, critical care medicine, and thrombocytopenia in infectious diseases. It is also committed to discovering drugs that regulate platelet activation or function inhibition, which are used for diseases related to thrombocytopenia and various thrombotic diseases such as atherosclerosis, coronary heart disease, and cerebral infarction. The company generates revenue from cell therapy and related drug development. This capital increase will also be used to develop novel platelet-derived drugs for age-related indications.
Who invested in HemaCell
14 investors across 6 rounds
See all investors in HemaCell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Questions about HemaCell
Who invested in HemaCell?
HemaCell has 14 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HemaCell raised?
HemaCell has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did HemaCell last raise money?
HemaCell's most recent round on record is a Series B, in Jun 2026.
What does HemaCell do?
, trading as HemaCell, is a stem cell biomedical company that focuses on the research and development of blood platelet medical products.
Where is HemaCell headquartered?
HemaCell is headquartered in Suzhou, China.
Which VCs invest in companies like HemaCell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at HemaCell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like HemaCell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.